Page last updated: 2024-10-26

dipyridamole and Peritoneal Carcinomatosis

dipyridamole has been researched along with Peritoneal Carcinomatosis in 3 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Research Excerpts

ExcerptRelevanceReference
" The maximum tolerated dose of etoposide was 175 mg/m2 per day when administered with dipyridamole at a fixed dose of 24 mg/m2 per day."2.67Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole. ( Braly, PS; Howell, SB; Isonishi, S; Kim, S; Kirmani, S; McClay, EF; Plaxe, SC, 1991)
"Chemical peritonitis was the dose-limiting toxicity."1.28Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole. ( Balis, FM; Cleary, SM; Goel, R; Horton, C; Howell, SB; Kirmani, S; Zimm, S, 1989)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19902 (66.67)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Isonishi, S1
Kirmani, S3
Kim, S1
Plaxe, SC1
Braly, PS1
McClay, EF1
Howell, SB3
Goel, R2
Cleary, SM1
Horton, C1
Balis, FM1
Zimm, S1

Trials

1 trial available for dipyridamole and Peritoneal Carcinomatosis

ArticleYear
Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole.
    Journal of the National Cancer Institute, 1991, May-01, Volume: 83, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Dose-R

1991

Other Studies

2 other studies available for dipyridamole and Peritoneal Carcinomatosis

ArticleYear
Novel approaches to intraperitoneal drug delivery.
    Acta medica Austriaca, 1989, Volume: 16, Issue:3-4

    Topics: Antineoplastic Agents; Dipyridamole; Dose-Response Relationship, Drug; Drug Evaluation; Drug Synergi

1989
Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Dipyridamole; Dr

1989